Phase II Study of Evaluation of Fractionated Radio-Immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-Cell Lymphoma.

Trial Profile

Phase II Study of Evaluation of Fractionated Radio-Immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs Epratuzumab Y-90 (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ALYSA
  • Most Recent Events

    • 10 Jun 2013 Updated interim results presented at Society of Nuclear Medicine and Molecular Imaging 2013 Annual Meeting, according to an Immunomedics media release.
    • 11 Dec 2012 Updated results were presented at the 2012 Annual Meeting of American Society of Hematology (ASH), according to an Immunomedics media release.
    • 05 Nov 2012 Results have been presented at the 54th American Society of Hematology (ASH) Annual Meeting according to an Immunomedics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top